The incidence in pediatrics is very low (about 3.5 per million per year according to a 2015 study) and therefore the data on the pathology very poor, especially on the therapeutic level. Without appropriate treatment, the disabling sequelae, even involving the vital prognosis, are significant. However, in paediatrics, therapeutic habits have been extrapolated from adult data and lack precision. Existing treatments are almost composed of immunomodulatory and/or immunosuppressive treatments. Different therapeutic lines have been introduced over the years and a better understanding of the pathology. More recently, biotherapies have been introduced in this pathology, but data on their effectiveness remain limited. Data on the evolution under therapy in children are thus still poor. Complications related to the pathology that can jeopardize the vital prognosis and the response to treatment for this pathology deserve to be studied in order to be known and if possible avoided. The aim of the study is to describe French practices and compare the lines of treatment proposed for juvenile atrophic polychondritis.
Study Type
OBSERVATIONAL
Enrollment
20
Service de Pédiatrie 1 - CHU de Strasbourg - France
Strasbourg, France
RECRUITINGTherapeutic effectiveness of the various treatments proposed depending on the degree of initial clinical involvement
The aim of this study is to bring together the experiences of the various reference and competence centers in France concerning the clinical presentation, management and follow-up of children with relapsing polychondritis.
Time frame: Files analysed retrospectively from from January 01, 2008 to December 31, 2022 will be examined
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.